News | February 10, 2026
Neuland Laboratories reports Rs 1,264.5 crore revenue for 9MFY26
The revenues this quarter are in line with the outlook we envisaged for the year
The revenues this quarter are in line with the outlook we envisaged for the year
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
The company’s EBITDA margin remained resilient above 20%
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Subscribe To Our Newsletter & Stay Updated
